Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Withdrawn 1Completed 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

NET 2Gastrointestinal 2Endocrine 2Head & Neck 1Dermatologic 1

Conditions

Neuroendocrine Tumors 11Somatostatinoma 6Insulinoma 4Glucagonoma 4Gastrinoma 4Carcinoma, Neuroendocrine 4Carcinoma, Islet Cell 3Zollinger-Ellison Syndrome 2Vipoma 2Pheochromocytoma 2Pancreatic Neoplasms 2Carcinoma, Medullary 2Carcinoid Tumor 2Adenoma, Islet Cell 2Pituitary Neoplasms 1Non functioning pancreatic endocrine tumor 1Neoplasms 1Multiple Endocrine Neoplasia Type 2b 1Multiple Endocrine Neoplasia Type 2a 1Multiple Endocrine Neoplasia Type 1 1Gastro-enteropancreatic neuroendocrine tumor 1Gastro-entero-pancreatic Neuroendocrine Tumors 1Carcinoma, Merkel Cell 1Adrenal Cortex Neoplasms 1

Interventions

vandetanib 5selpercatinib 4Everolimus 4cabozantinib 3Sorafenib 3lenvatinib 2Trastuzumab 2Temozolomide 2Sunitinib 2Octreotide 2Gefitinib 2Capecitabine 2veliparib 1vatalanib 1tumor necrosis factor-alpha, CNGRC fusion protein, human 1tipifarnib 1temsirolimus 1tanespimycin 1sargramostim 1sacubitril and valsartan sodium hydrate drug combination 1pralsetinib 1pentetreotide 1pazopanib 1motesanib diphosphate 1mercaptoundecahydrododecaborate 1lutetium Lu 177 dotatate 1cixutumumab 1aldesleukin 1Vorinostat 1Vinorelbine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Carcinoma, Medullary × Capecitabine × Endocrine × Clear all
NCT02831179 2017-09-28

Veliparib, Capecitabine, and Temozolomide in Patients With Advanced, Metastatic, and Recurrent Neuroendocrine Tumor

Vanderbilt-Ingram Cancer Center

Phase 1 Withdrawn
DermatologicEndocrineGastrointestinalNET

Non functioning pancreatic endocrine tumor, Adrenal Cortex Neoplasms, Carcinoid Tumor, Vipoma, Glucagonoma, Insulinoma, Pheochromocytoma, Somatostatinoma, Zollinger-Ellison Syndrome, Carcinoma, Merkel Cell, Carcinoma, Medullary, Neuroendocrine Tumors, Multiple Endocrine Neoplasia Type 1, Multiple Endocrine Neoplasia Type 2a, Multiple Endocrine Neoplasia Type 2b

NCT00869050 2016-07-25

Capecitabine and Temozolomide for Neuroendocrine Cancers

Columbia University

Phase 2 Completed
41 enrolled 9 charts
EndocrineGastrointestinalNET

Carcinoid Tumor, Vipoma, Pancreatic Neoplasms, Pheochromocytoma, Somatostatinoma, Zollinger-Ellison Syndrome, Gastrinoma, Carcinoma, Medullary, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡